Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Rapid Publication

Human Pancreatic Duct Cells Exert Tissue Factor-Dependent Procoagulant Activity

Relevance to Islet Transplantation

  1. Claire Beuneu12,
  2. Olivier Vosters12,
  3. Babak Movahedi23,
  4. Myriam Remmelink4,
  5. Isabelle Salmon4,
  6. Daniel Pipeleers23,
  7. Olivier Pradier1,
  8. Michel Goldman12 and
  9. Valérie Verhasselt12
  1. 1Laboratory of Experimental Immunology and Institute for Medical Immunology, Université Libre de Bruxelles-ULB, Erasme Hospital, Brussels, Belgium
  2. 2Juvenile Diabetes Research Foundation Center for β-Cell Therapy in Europe, Brussels, Belgium
  3. 3Diabetes Research Center, Vrije Universiteit Brussels-VUB, Brussels, Belgium
  4. 4Laboratory of Pathology, Université Libre de Bruxelles-ULB, Erasme Hospital, Brussels, Belgium
  1. Address correspondence and reprint requests to Michel Goldman, MD, PhD, Laboratory of Experimental Immunology, Université Libre de Bruxelles, Hôpital Erasme, 808 Route de Lennik, B-1070 Brussels, Belgium. E-mail: mgoldman{at}ulb.ac.be
Diabetes 2004 Jun; 53(6): 1407-1411. https://doi.org/10.2337/diabetes.53.6.1407
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Relevance to Islet Transplantation

Abstract

Activation of the coagulation cascade contributes to early graft loss and intraportal thrombotic events in clinical islet transplantation. Although these complications were shown to be related to the presence of tissue factor in human islet preparations, the contribution of duct cells, which represent a major contaminant of clinical islet isolates, has not been specified so far. Herein, we used flow cytometry, immunohistochemistry, RT-PCR, and functional coagulation assays to demonstrate that duct cells exert a potent factor VII-dependent procoagulant activity related to their expression of tissue factor. Both the classical membrane-bound and the recently described soluble form of tissue factor were shown to be synthesized by duct cells. We conclude that contaminating duct cells contribute to early β-cell damage after islet transplantation through their involvement in tissue factor-mediated thrombotic and inflammatory events.

  • asTF, alternatively spliced tissue factor
  • CK19, cytokeratin 19
  • mAb, monoclonal antibody
  • PBMC, peripheral blood mononuclear cell
  • PCA, procoagulant activity
  • TF, tissue factor

Early loss of functional β-cells after islet transplantation represents a major limitation of this therapeutic modality for type 1 diabetes, even with the most efficient protocols currently available (1,2). Recent observations by Korsgren, Nilsson, and coworkers (3–5) provided convincing evidence that this complication is related, at least in part, to activation of the coagulation cascade by islet isolates. Indeed, the procoagulant state induced by islet transplantation can culminate in portal vein thrombosis (6). The demonstration that endocrine cells express tissue factor (TF) provided a plausible cause for the thrombotic reaction elicited by human islet suspensions (5). However, it has been established (7,8) that islet suspensions prepared for clinical transplantation contain a significant proportion (up to 40%) of nonendocrine duct cells. Indeed, even in the most successful report by Shapiro et al. (2), percentages of β-cells in clinical preparations never exceeded 52%, with a mean percentage of 24%. The contaminating duct cells have already been suggested to directly contribute to β-cell damage through their production of nitric oxide (9). Herein, we assessed the impact of duct cells on the coagulation system to address their possible involvement in the thrombotic reaction elicited by islet isolates.

RESEARCH DESIGN AND METHODS

Cell preparations.

Human pancreatic duct cells were isolated from pancreata obtained from adult heart-beating organ donors as previously described (9). The organs were procured by European hospitals affiliated with the Eurotransplant Foundation (Leiden, the Netherlands) and sent to the Human β-Cell Bank in Brussels (Belgium) for the preparation of isolated fractions. Collagenase digests were separated by Ficoll gradient purification into an islet fraction and an exocrine fraction. The exocrine fraction was cultured in serum-free medium for at least 4 days, leading to a preparation enriched in duct cells. As recently reported (10), the purity of these duct cell preparations was routinely >90–95% as assessed by cytokeratin 19 (CK19) staining. The culture medium consisted of HAM’s F10 with 6 mmol/l glucose, supplemented with 0.5% BSA, 0.1 mg/ml streptomycin, 125 units/ml penicillin, and 2 mmol/l l-glutamine. Thereafter, cells were either maintained in a serum-free medium (cultures in suspension) or dissociated in a calcium-free medium and cultured with 10% FCS to obtain monolayers. Human adenocarcinoma pancreatic duct cell line (CAPAN-2) was cultured as previously described (11). In one set of experiments, β-cells and duct cells were directly isolated using fluorescence-activated cell sorting, as previously described (9). As control, peripheral blood mononuclear cells (PBMCs) from healthy volunteers were activated during 6 h with 1 μg/ml lipopolysaccharide from E. coli (serotype 0128:B12; Sigma Chemicals, Bornem, Belgium).

Procoagulant activity assay.

Procoagulant activity (PCA) was determined in duplicates by a single-stage clotting assay on culture supernatants or on cell extracts realized in PBS by repetitive freezing. Each sample (100 μl) was incubated at 37°C for 1 min with 100 μl of normal citrated plasma before the initiation of clotting by the addition of 100 μl of 25 mmol/l CaCl2. Clotting time was recorded with a KC10 apparatus (Amelung, Lemgo, Germany), and PCA (in milliunits per milliliter) was determined by reference to a standard curve generated with a commercial rabbit thromboplastin (BioMérieux, Marcy l’Etoile, France). The amount of thromboplastin that yielded a clotting time of 12.4 s was assigned a value of 1 unit. To determine the role of the TF/factor VII pathway in the PCA, experiments were performed with factor VII-deficient plasma (Dade Behring, Anderlecht, Belgium). The number of cells in the extracts was determined by counting or DNA measurement.

Flow cytometry analysis.

Cells were washed in PBS supplemented with 1% BSA and 10% pooled human serum and incubated for 20 min at 4°C with the fluorescein isothiocyanate-conjugated IgG1 monoclonal antibody (mAb) against TF no. 4508CJ (American Diagnostica, Andresy, France) or the corresponding isotype-matched control mAb (Becton Dickinson, Erembodegem, Belgium). Cell fluorescence was analyzed using a FACScan flow cytometer (Becton Dickinson).

Immunohistochemistry studies.

Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded human pancreatic specimens. Five-micron-thick sections were cut onto coated slides and deparaffined by routine techniques. After antigen retrieval in EDTA and microwave pretreatment, the sections were incubated with a mouse anti-TF mAb (IgG1 n4509; American Diagnostica) or a mouse anti-CK19 mAb (clone RCK108; Dako, Merelbeke, Belgium) at 1/100 dilution. Negative controls were obtained by omitting the primary antibody. Labeling was revealed by the streptavidin-biotin-peroxidase complex (Dako).

RT-PCR.

mRNA was extracted from 0.2 × 106 duct cells or 0.5 × 106 PBMCs using the MagNA Pure mRNA extraction kit on the MagNA Pure instrument (Roche Applied Science, Brussels, Belgium) following the manufacturer’s instructions. One-step RT-PCR was performed on a Lightcycler instrument (Roche Applied Science) with primers synthesized at Biosource Europe (Nivelles, Belgium). RT-PCR for TF or β-actin was realized with the following primers: TF: sense primer, 5′-TGAATGTGACCGTAGAAGATGA-3′; antisense primer, 5′-GGAGTTCTCCTTCCAGCTCT-3′; and β-actin: sense primer, 5′-GGTCAGAAGGATTCCTATG-3′; antisense primer, 5′-GGTCTCAAACATGATCTGGG-3′. Products were separated by electrophoresis on 2% agarose and visualized with ethidium bromide. We also developed a real-time RT-PCR method using the following primers and probes: TF sense primer, 5′-GGGAATTCAGAGAAATATTCTACATCA-3′, TF antisense primer, 5′-TAGCCAGGATGATGACAAGGA-3′; alternatively spliced TF (asTF) sense primer, 5′-TCTTCAAGTTCAGGAAAGAAATATTCT-3′; asTF antisense primer, 5′-CCAGGATGATGACAAGGATGA-3′; and probe, 5′-TGGAGCTGTGGTATTTGTGGTCA-3′.

Tubing loop model.

A whole-blood experiment protocol was adapted from a model previously described (5). Loops made of polyvinylchloride tubing (inner diameter 6.3 mm and length 390 mm) and treated with a Corline heparin surface were purchased from Corline (Uppsala, Sweden). Loops were supplemented with cell samples in 150 μl PBS or with PBS alone before blood addition. When indicated, samples were preincubated at room temperature for 10 min with a neutralizing mAb against TF (IgG1 no. 4509) or PBS and added to the loops after two washing steps. Nonanticoagulated blood (5 ml) from healthy volunteers was added to each loop. To generate a blood flow of about 45 ml/min, loop devices were placed on a platform rocker inside a 37°C incubator. Blood samples were collected into EDTA (4.1 mmol/l final concentration) and citrate (12.9 mmol/l final concentration) tubes before and 30 min after perfusion began. Platelets were counted using a CellDyn 4000 automate (Abbott Laboratories, Abbott Park, IL), and fibrinogen was determined using a Behring coagulation system (Dade Behring).

RESULTS

PCA of pancreatic cell preparations in human plasma.

In a preliminary set of experiments, we compared the PCA in human plasma of several cell preparations obtained from human pancreata. As shown in Table 1, we first found that both the endocrine and exocrine fractions induced significant PCA. When the exocrine fraction was cultured in conditions resulting in duct cell enrichment (>95%), PCA increased to reach values three- to sixfold above that of the endocrine fraction. The PCA activity of the enriched duct cell preparations was factor VII-dependent since it was not observed in factor VII-depleted plasma. In accordance with these findings obtained on primary duct cells, we observed that the CAPAN-2 pancreatic duct cell line exerted a factor VII-dependent PCA that was also present in the culture supernatants of this cell line.

TF expression by duct cells.

The factor VII dependence of the duct cell-associated PCA strongly suggested the involvement of TF. TF expression by primary duct cells was first documented by flow cytometry (Fig. 1A). Additional immunohistochemical studies were conducted to confirm the constitutive expression of TF on duct cells in vivo. First, we confirmed a positive staining of islets for TF (data not shown). As shown in Fig. 1B, a clear staining for TF was observed on cells that express CK19, a marker specific for epithelial cells. The staining for TF was cytoplasmic and concentrated at the apical side.

Using RT-PCR, we confirmed that both the CAPAN-2 duct cell line and primary duct cells express TF mRNA (Fig. 2A). Interestingly, both the classical form and the recently described alternatively spliced variant (12) of TF mRNA were detected in the duct cell extracts. For control, we documented the upregulation of TF mRNA expression in PBMCs upon activation by bacterial lipopolysaccharide. In this cell type, the classical form of TF mRNA was clearly induced, whereas asTF was barely detected. In additional experiments, we used a real-time RT-PCR method to quantify TF and asTF mRNA expression in β-cells and duct cells directly purified by using flow-activated cell sorting. As shown in Fig. 2B (which is representative of three independent experiments), the expression of both TF and asTF mRNA was higher in duct cells (87% pure) than in β-cells (74% pure) obtained from the same donor.

PCA of primary duct cells in whole blood.

To investigate the PCA of duct cells in a model closer to the in vivo situation, we adapted the tubing loop system that was used to demonstrate the thrombotic reaction induced by islet preparations (5). This model is based on the injection of nonanticoagulated blood in plastic loops in which the inner surface is coated with heparin to prevent contact-dependent blood coagulation, thus allowing the investigation of coagulation in the presence of platelets. Blood coagulation was assessed by macroscopic examination for the presence of clots and by monitoring platelet counts and fibrinogen levels, which drop as a consequence of coagulation activation. As shown in Table 2, we found that as few as 103 duct cells added to 5 ml of blood were sufficient to induce clot formation within 30 min. This was associated with a dramatic drop in platelet counts and a complete consumption of fibrinogen. In three independent experiments, pretreatment of duct cells with an anti-TF mAb prevented the formation of visible clots and reduced the drop in platelet counts and fibrinogen levels.

DISCUSSION

The demonstration that the CAPAN-2 duct cell line expresses TF is in line with previous studies (13) showing the presence of TF in pancreatic ductal adenocarcinoma. As far as the normal pancreas is concerned, TF expression was previously documented (14) during embryogenesis, but not in adult tissue. Development of more sensitive immunostaining techniques using different anti-TF antibodies probably explains the recent demonstration (5) of TF expression in human islets. In our study, we confirmed this observation and also provided evidence for TF expression by duct cells in normal pancreas (Fig. 2). The latter finding is consistent with the expression of TF by normal epithelial cells in breast and kidney (15,16).

Interestingly, duct cells were shown to express the classical TF mRNA, encoding the membrane form of TF as well as asTF, which encodes the molecule-soluble form (12). It has been suggested that asTF could be involved in the propagation of the coagulation in blood and lead to the formation of macroscopic thrombi (12). Expression of asTF by duct cells might thus contribute, possibly along with the release of TF in microparticles (17), to the PCA present in the supernatants of duct cell cultures.

The relevance of our observations to islet transplantation is suggested by experimental observations (18) in rats showing the formation of thrombi shortly after transplantation, particularly around the nonendocrine tissue that contaminates islet preparations. Furthermore, there is also clinical evidence (6) that insufficient islet purification can promote development of portal vein thrombosis. In allogeneic as well as autologous islet transplants, the regular use of heparin might contribute to limit these thrombotic complications. Activation of coagulation by TF could not only result in thrombotic events but also elicit an inflammatory reaction involving upregulation of adhesion molecule expression and chemokine production (19,20). In the context of islet transplantation, the so-called instant blood-mediated inflammatory reaction likely contributes to early β-cell loss (5). It could also enhance graft immunogenicity, thereby promoting transplant rejection (21). Our findings demonstrate that contaminating duct cells can contribute to this post-islet transplant blood-mediated inflammatory reaction originally described (5) as a consequence of TF expression by endocrine cells.

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

Primary duct cells express TF. A: Primary duct cells cultured in monolayers were dissociated and analyzed by flow cytometry after staining by either anti-TF IgG mAb (thick line) or corresponding control isotype mAb (dotted line). A similar staining was found in four independent experiments. B: Immunohistochemical analysis for TF and CK19 was performed on serial sections of formalin-fixed, paraffin-embedded, human normal pancreatic specimens. Left panel: TF staining of epithelial cells. Right panel: CK19 staining on a consecutive section (original magnification 400×). FITC, fluorescein isothiocyanate.

FIG. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 2.

Duct cells express the two forms of TF mRNA. A: mRNA extracted from CAPAN-2 cells, cultured primary duct cells, or resting or lipopolysaccharide-activated PBMCs were analyzed by RT-PCR for TF and β-actin. One representative experiment out of three is shown. TF indicates the size of classical TF mRNA (407 bp) encoding the membrane form; asTF indicates the size (247 bp) of the alternatively spliced variant encoding the soluble form. B: Quantification of TF and asTF mRNA using real-time RT-PCR in β-cells (74% pure) and duct cells (87% pure) from the same donor. One representative experiment out of three is shown. Results are expressed per 106 mRNA copies of β-actin.

View this table:
  • View inline
  • View popup
TABLE 1

PCA of pancreatic cell preparations in plasma

View this table:
  • View inline
  • View popup
TABLE 2

TF-dependent PCA of cultured duct cells in whole blood

Acknowledgments

This work was supported by a grant from the Juvenile Diabetes Research Foundation to the Juvenile Diabetes Research Foundation Center for β-Cell Therapy in Europe. C.B. and V.V. are supported by the Fonds National de la Recherche Scientifique (Belgium). O.V. is supported by SMB-Galephar, Belgium.

The authors thank P. Stordeur for providing the primers and probes for RT-PCR and L. Bouwens (Cell Differentiation Unit, Brussels, Belgium) for providing the CAPAN-2 cell lines.

Footnotes

  • Posted on the World Wide Web at http://diabetes.diabetesjournals.org on 7 April 2004.

    • Accepted March 25, 2004.
    • Received February 13, 2004.
  • DIABETES

REFERENCES

  1. ↵
    Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock GL, Larsen I, Shapiro AM: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes50 :710 –719,2001
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med343 :230 –238,2000
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, Brandhorst H, Bretzel RG, Elgue G, Larsson R, Nilsson B, Korsgren O: Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes48 :1907 –1914,1999
    OpenUrlAbstract
  4. Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O, Nilsson B: Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes51 :1779 –1784,2002
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Kallen R, Ostraat O, Salmela K, Tibell A, Tufveson G, Elgue G, Nilsson EK, Korsgren O, Nilsson B: Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet360 :2039 –2045,2002
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Shapiro AM, Lakey JR, Rajotte RV, Warnock GL, Friedlich MS, Jewell LD, Kneteman NM: Portal vein thrombosis after transplantation of partially purified pancreatic islets in a combined human liver/islet allograft. Transplantation59 :1060 –1063,1995
    OpenUrlCrossRefPubMed
  7. ↵
    Ling Z, Pipeleers DG: Prolonged exposure of human beta cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation. J Clin Invest98 :2805 –2812,1996
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Keymeulen B, Ling Z, Gorus FK, Delvaux G, Bouwens L, Grupping A, Hendrieckx C, Pipeleers-Marichal M, Van Schravendijk C, Salmela K, Pipeleers DG: Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia41 :452 –459,1998
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Pavlovic D, Chen MC, Bouwens L, Eizirik DL, Pipeleers D: Contribution of ductal cells to cytokine responses by human pancreatic islets. Diabetes48 :29 –33,1999
    OpenUrlAbstract
  10. ↵
    Vosters O, Beuneu C, Nagy N, Movahedi B, Aksoy E, Salmon I, Pipeleers D, Goldman M, Verhasselt V: CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of proinflammatory cytokines. Diabetologia. In press
  11. ↵
    De Breuck S, Lardon J, Rooman I, Bouwens L: Netrin-1 expression in fetal and regenerating rat pancreas and its effect on the migration of human pancreatic duct and porcine islet precursor cells. Diabetologia46 :926 –933,2003
    OpenUrlCrossRefPubMed
  12. ↵
    Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y: Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med9 :458 –462,2003
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC: Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg82 :1101 –1104,1995
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Luther T, Flossel C, Mackman N, Bierhaus A, Kasper M, Albrecht S, Sage EH, Iruela-Arispe L, Grossmann H, Strohlein A, Zhang Y, Nawroth PP, Carmeliet P, Loskutoff DJ, Muller M: Tissue factor expression during human and mouse development. Am J Pathol149 :101 –113,1996
    OpenUrlPubMedWeb of Science
  15. ↵
    Luther T, Flossel C, Albrecht S, Kotzsch M, Muller M: Tissue factor expression in normal and abnormal mammary gland (Letter). Nat Med2 :491 –492,1996
    OpenUrlPubMed
  16. ↵
    Sugawara T, Yamabe H, Osawa H, Kaizuka M, Shirato K, Nakamura M, Tamura M, Okumura K: Tissue factor pathway inhibitor production by human proximal tubular epithelial cells in culture. Thromb Res110 :141 –147,2003
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A96 :2311 –2315,1999
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Franklin WA, Schulak JA, Reckard CR: The fate of transplanted pancreatic islets in the rat. Am J Pathol94 :85 –95,1979
    OpenUrlPubMed
  19. ↵
    Dugina TN, Kiseleva EV, Chistov IV, Umarova BA, Strukova SM: Receptors of the PAR family as a link between blood coagulation and inflammation. Biochemistry (Mosc)67 :65 –74,2002
    OpenUrlCrossRefPubMed
  20. ↵
    Bokarewa MI, Morrissey JH, Tarkowski A: Tissue factor as a proinflammatory agent. Arthritis Res4 :190 –195,2002
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Le Moine A, Goldman M: Contributions of innate immunity to allograft rejection and survival. Curr Opin Organ Tranplant8 :2 –6,2003
    OpenUrl
PreviousNext
Back to top

In this Issue

June 2004, 53(6)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human Pancreatic Duct Cells Exert Tissue Factor-Dependent Procoagulant Activity
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human Pancreatic Duct Cells Exert Tissue Factor-Dependent Procoagulant Activity
Claire Beuneu, Olivier Vosters, Babak Movahedi, Myriam Remmelink, Isabelle Salmon, Daniel Pipeleers, Olivier Pradier, Michel Goldman, Valérie Verhasselt
Diabetes Jun 2004, 53 (6) 1407-1411; DOI: 10.2337/diabetes.53.6.1407

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Human Pancreatic Duct Cells Exert Tissue Factor-Dependent Procoagulant Activity
Claire Beuneu, Olivier Vosters, Babak Movahedi, Myriam Remmelink, Isabelle Salmon, Daniel Pipeleers, Olivier Pradier, Michel Goldman, Valérie Verhasselt
Diabetes Jun 2004, 53 (6) 1407-1411; DOI: 10.2337/diabetes.53.6.1407
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Regeneration of Pancreatic Islets After Partial Pancreatectomy in Mice Does Not Involve the Reactivation of Neurogenin-3
  • Abnormal Glucose Homeostasis due to Chronic Hyperresistinemia
Show more Rapid Publication

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.